Company intelligence / Profile preview

Spine Restoration

New York, New York, United Statesspinerestorationllc.com ↗

Ownership: Private
Development stage: Commercial

Overview

SB‑01 for injection, a synthetic peptide antagonist of TGF-Beta, has advanced to Phase 3 clinical trials for degenerative disc disease. The therapy aims to reduce pain, restore function, and slow or halt pathological progression in DDD patients. Clinical results are not detailed in public sources as of June 2025; however, the candidate represents a first-in-class approach with potential benefits over current non-surgical options.

Therapeutic areas: RheumatologyNeurology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Not publicly disclosed as of June 2025. The company mentions partnerships with pharmaceutical companies and scientists but does not list specific names.

Beyond the preview

Go deeper on Spine Restoration.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spine Restoration.

Explore the full profile